Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania
Executive Summary
Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.
You may also be interested in...
Finance Watch: Lyell Raises $425m As Eight Biopharmas Go Public In One Week
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.
Pfizer’s COVID-19 Franchise Dominates Best-Seller List
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.